211 related articles for article (PubMed ID: 8962459)
21. P-value calculation for multistage phase II cancer clinical trials.
Jung SH; Owzar K; George SL; Lee T
J Biopharm Stat; 2006; 16(6):765-75; discussion 777-83. PubMed ID: 17146978
[TBL] [Abstract][Full Text] [Related]
22. A parallel phase I/II clinical trial design for combination therapies.
Huang X; Biswas S; Oki Y; Issa JP; Berry DA
Biometrics; 2007 Jun; 63(2):429-36. PubMed ID: 17688495
[TBL] [Abstract][Full Text] [Related]
23. A group-sequential design for clinical trials with treatment selection.
Stallard N; Friede T
Stat Med; 2008 Dec; 27(29):6209-27. PubMed ID: 18792085
[TBL] [Abstract][Full Text] [Related]
24. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials.
Thall PF; Russell KE
Biometrics; 1998 Mar; 54(1):251-64. PubMed ID: 9544520
[TBL] [Abstract][Full Text] [Related]
25. On the estimation of the binomial probability in multistage clinical trials.
Jung SH; Kim KM
Stat Med; 2004 Mar; 23(6):881-96. PubMed ID: 15027078
[TBL] [Abstract][Full Text] [Related]
26. Two-stage designs for phase II cancer trials with ordinal responses.
Stallard N; Cockey L
Contemp Clin Trials; 2008 Nov; 29(6):896-904. PubMed ID: 18703164
[TBL] [Abstract][Full Text] [Related]
27. Optimizing randomized phase II trials assessing tumor progression.
Stone A; Wheeler C; Carroll K; Barge A
Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
[TBL] [Abstract][Full Text] [Related]
28. Multinomial phase II cancer trials incorporating response and early progression.
Zee B; Melnychuk D; Dancey J; Eisenhauer E
J Biopharm Stat; 1999 May; 9(2):351-63. PubMed ID: 10379698
[TBL] [Abstract][Full Text] [Related]
29. A two-stage phase II trial design utilizing both primary and secondary endpoints.
Lin X; Allred R; Andrews G
Pharm Stat; 2008; 7(2):88-92. PubMed ID: 17252536
[TBL] [Abstract][Full Text] [Related]
30. Optimal two-stage designs allowing flexibility in number of subjects for phase II clinical trials.
Masaki N; Koyama T; Yoshimura I; Hamada C
J Biopharm Stat; 2009 Jul; 19(4):721-31. PubMed ID: 20183436
[TBL] [Abstract][Full Text] [Related]
31. A comparison of methods for adaptive treatment selection.
Friede T; Stallard N
Biom J; 2008 Oct; 50(5):767-81. PubMed ID: 18932136
[TBL] [Abstract][Full Text] [Related]
32. Sequential designs for phase III clinical trials incorporating treatment selection.
Stallard N; Todd S
Stat Med; 2003 Mar; 22(5):689-703. PubMed ID: 12587100
[TBL] [Abstract][Full Text] [Related]
33. Optimal two-stage designs for clinical trials based on safety and efficacy.
Thall PF; Cheng SC
Stat Med; 2001 Apr; 20(7):1023-32. PubMed ID: 11276033
[TBL] [Abstract][Full Text] [Related]
34. An extension of the single threshold design for monitoring efficacy and safety in phase II clinical trials.
Brutti P; Gubbiotti S; Sambucini V
Stat Med; 2011 Jun; 30(14):1648-64. PubMed ID: 21520453
[TBL] [Abstract][Full Text] [Related]
35. Phase I (or phase II) dose-ranging clinical trials: proposal of a two-stage Bayesian design.
Zohar S; Chevret S
J Biopharm Stat; 2003 Feb; 13(1):87-101. PubMed ID: 12635905
[TBL] [Abstract][Full Text] [Related]
36. Adaptive two-stage designs in phase II clinical trials.
Banerjee A; Tsiatis AA
Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
[TBL] [Abstract][Full Text] [Related]
37. A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial.
Bekele BN; Shen Y
Biometrics; 2005 Jun; 61(2):343-54. PubMed ID: 16011680
[TBL] [Abstract][Full Text] [Related]
38. One- and two-stage designs for phase II window studies.
Chang MN; Devidas M; Anderson J
Stat Med; 2007 Jun; 26(13):2604-14. PubMed ID: 17211853
[TBL] [Abstract][Full Text] [Related]
39. [New trends in assessment in anticancer treatments by phase II clinical trials].
Medioni JR; Rycke YD; Asselain B
Bull Cancer; 2000 Jul; 87(7-8):551-6. PubMed ID: 10969213
[TBL] [Abstract][Full Text] [Related]
40. Interval estimation of binomial proportion in clinical trials with a two-stage design.
Tsai WY; Chi Y; Chen CM
Stat Med; 2008 Jan; 27(1):15-35. PubMed ID: 17566141
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
